孕激素治疗子宫内膜癌的分子预后标志物
本研究回顾性分析了1999至2020年间接受孕激素治疗的105例子宫内膜非典型增生或内膜样癌患者,12个月总缓解率为61.0%。非典型增生患者缓解率(73.1%)高于1-2级内膜样癌(54.8%)。p53异常表达和错配修复缺陷(MMRd)与无缓解相关,提示分子分型有助于筛选适合非手术管理的患者。
要点
- 孕激素治疗12个月总缓解率为61.0%,非典型增生患者缓解率高于内膜样癌。
- p53异常表达和MMRd患者对孕激素治疗无缓解,建议治疗前进行分子检测。
- MRI提示肌层浸润与孕激素无缓解相关,治疗前影像评估很重要。
核心结论
- 孕激素治疗子宫内膜非典型增生和早期内膜样癌的12个月总缓解率为61.0%。
- p53异常表达和错配修复缺陷(MMRd)与孕激素治疗无缓解相关。
- 年龄较大和MRI提示肌层浸润与孕激素治疗无缓解相关。
研究设计与样本
- 单中心回顾性队列研究,纳入1999年1月至2020年12月接受口服或宫内孕激素治疗的子宫内膜非典型增生或内膜样癌患者105例。
- 缓解定义为12个月时病理完全或部分缓解。
- 对活检组织进行免疫组化染色和二代测序,检测p53异常表达、错配修复缺陷(MMRd)和POLE突变。
- 采用Fisher精确检验和t检验分析缓解与临床及分子因素的相关性。
主要发现
- 105例患者平均BMI为47.7(标准差16.7)。
- 12个月总缓解率为61.0%。
- 非典型增生患者缓解率为73.1%(30/41),1-2级内膜样癌患者缓解率为54.8%(34/62)。
- 年龄较大和MRI提示肌层浸润与孕激素无缓解相关。
临床怎么用
- 对不适合手术的子宫内膜非典型增生或早期内膜样癌患者,可考虑孕激素治疗。
- 治疗前应进行MRI评估肌层浸润情况,并考虑分子检测(p53、MMRd)以预测孕激素治疗反应。
局限性
- 单中心回顾性研究,样本量有限(105例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While most cases of early stage endometrioid endometrial cancer (EEC) are treated surgically, progestin therapy is an alternative for patients who are not surgical candidates. This study aimed to evaluate a single institution's response rates to hormonal therapy and to identify clinical and molecular factors associated with response. METHODS: We conducted a retrospective cohort study of patients with EEC and atypical hyperplasia (AH) managed with progestin (oral or IUD) from 01/1999 to 12/2020. Patients with a complete or partial pathologic response at 12 months were considered as responders. Immunohistochemical stains as well as next generation sequencing was performed on biopsy tissue to identify abnormal p53 expression, mismatch repair deficiency (MMRd), and POLE mutations. We measured association of response to clinical and molecular factors using Fisher's exact tests and t-tests. RESULTS: 105 patients diagnosed with AH/EEC treated with IUD or oral progesterone were included. Mean BMI was 47.7 (SD: 16.7). At 12 months, overall response was 61.0%. Response rate was higher in patients with AH (73.1%, 30/41) than in grade 1-2 EEC (54.8%, 34/62). Sixty-four patients had molecular testing. Both patients with abnormal p53 expression and 3 of 4 MMRd were non-responders. Older age and myometrial invasion on MRI were associated with non-response to progesterone. CONCLUSIONS: Selecting candidates for nonsurgical management of endometrial cancer remains challenging. The association of myometrial invasion to response illustrates the importance of pretreatment imaging. Given non-response in 3 of 4 MMRd and both p53 mutated tumors, molecular testing should be considered in all these patients.
引用
- Kailasam A, De Vitis L, Murphy B, et al. The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer. Gynecol Oncol. 2026. PMID: 41886941. doi:10.1016/j.ygyno.2026.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。